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Sex-determining region Y (SRY) box 2 (SOX2) haploinsufficiency causes a form of hypopituitarism in humans 
that is characterized by gonadotrophin deficiency known as hypogonadotrophic hypogonadism. Here, we 
conditionally deleted Sox2 in mice to investigate the pathogenesis of hypogonadotrophic hypogonadism. First, 
we found that absence of SOX2 in the developing Rathke pouch of conditional embryos led to severe ante-
rior lobe hypoplasia with drastically reduced expression of the pituitary-specific transcription factor POU 
class 1 homeobox 1 (POU1F1) as well as severe disruption of somatotroph and thyrotroph differentiation. 
In contrast, corticotrophs, rostral-tip POU1F1-independent thyrotrophs, and, interestingly, lactotrophs and 
gonadotrophs were less affected. Second, we identified a requirement for SOX2 in normal proliferation of 
periluminal progenitors; in its absence, insufficient precursors were available to produce all cell lineages of the 
anterior pituitary. Differentiated cells derived from precursors exiting cell cycle at early stages, including cor-
ticotrophs, rostral-tip thyrotrophs, and gonadotrophs, were generated, while hormone-producing cells origi-
nating from late-born precursors, such as somatotrophs and POU1F1-dependent thyrotrophs, were severely 
reduced. Finally, we found that 2 previously characterized patients with SOX2 haploinsufficiency and asso-
ciated hypogonadotrophic hypogonadism had a measurable response to gonadotropin-releasing hormone 
(GnRH) stimulation, suggesting that it is not the absence of gonadotroph differentiation, but rather the defi-
cient hypothalamic stimulation of gonadotrophs, that underlies typical hypogonadotrophic hypogonadism.
Introduction
Heterozygous mutations in sex-determining region Y (SRY) box 2 
(SOX2) have been associated with major eye abnormalities (i.e., 
anophthalmia, microphthalmia, and coloboma), hypopituitarism 
characterized by pituitary hypoplasia on imaging, and gonadotro-
phin deficiency (hypogonadotrophic hypogonadism [HH]) (1). 
In addition to hypoplasia of the corpus callosum, hypothalamic 
hamartoma, and hippocampal malformation, patients carrying 
inactivating SOX2 mutations frequently manifest other defects, 
such as esophageal atresia, sensorineural hearing loss, pituitary 
masses, and learning difficulties. Numerous nonsense, frameshift, 
and missense mutations, leading to the expression of SOX2 pro-
teins with compromised function, as well as chromosomic dele-
tions encompassing SOX2 have been identified (2).
SOX2 is a member of the SRY-related HMG box B1 (SOXB1) 
subfamily of transcription factors, which also includes SOX1 and 
SOX3 (3). In both humans and mice, SOX2 is widely expressed 
during embryonic development throughout the entire epithelium 
of the brain and posterior neural tube, including the cortex, hip-
pocampus, cerebellum, and spinal cord (4). In addition, persistent 
SOX2 expression is observed in the developing eye, in particular in 
the lens, neural retina, and optic nerve, and also in the prosensory 
region of the cochlea (5, 6). Endoderm-derived organs such as the 
trachea, esophagus, stomach, and posterior gut also express SOX2 
during embryogenesis (4, 7). Of relevance, both the hypothalamus 
and Rathke pouch (RP) (the primordium of the anterior and inter-
mediate pituitary lobes) normally express SOX2, but expression is 
not observed in the infundibulum (a recess at the floor of the hypo-
thalamus) and the posterior pituitary (PP) lobe in humans (4, 8).
The pituitary gland is of dual embryonic origin. The anterior 
pituitary (AP) derives from RP, a region of the oral ectoderm under-
lying the developing diencephalon, and comprises the anterior and 
intermediate lobes. The PP is of neural origin and develops from a 
recess in the ventral midline of the diencephalon (the infundibu-
lum). By late gestation, the anterior lobe contains 5 hormone-pro-
ducing cell types; these include somatotrophs, lactotrophs, thyro-
trophs, gonadotrophs, and corticotrophs, which secrete growth 
hormone (GH), prolactin (PRL), thyroid-stimulating hormone 
(TSH), gonadotrophins (follicle-stimulating hormone [FSH] and 
luteinizing hormone [LH]), and ACTH, respectively (1, 9). The 
intermediate lobe contains melanotrophs, which express mela-
notrophin (MSH). Finally, the PP contains no endocrine cell types, 
but is instead richly endowed with axonal projections from hypo-
thalamic neurons. Two independent birth-dating studies in mice 
have highlighted that the vast majority of AP cell types exit the cell 
cycle concurrently between 11.5 and 13.5 dpc (10, 11). At 13.5 dpc, 
a transitional zone composed of noncycling undifferentiated pre-
cursors appears immediately ventral to the periluminal area and is 
marked by the expression of CDK1NC (p57Kip2) and cyclin E. These 
cells do not express any markers of terminal differentiation (12). It 
is now believed that this transitional zone contains a finite pool of 
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precursors, which will initiate commitment into specific AP cell lin-
eages. Rostral-tip thyrotroph, corticotroph, and gonadotroph pre-
cursors exit the cell cycle first from 11.5 dpc. This is closely followed 
by the POU class 1 homeobox 1–dependent (POU1F1-dependent 
or Pit1-dependent) lineage, comprising thyrotrophs, lactotrophs, 
and somatotrophs. Finally, melanotroph precursors, which com-
pose the intermediate lobe, have been shown to exit the cell cycle 
last, after all the anterior lobe cell types (11).
The functioning of the pituitary gland is primarily regulated by 
the parvocellular and magnocellular neurons, which reside in dis-
tinct nuclei in the hypothalamus. Specifically, the parvocellular 
axonal projections remain within the brain, where they terminate 
at the median eminence, a central “hub” allowing the release of 
parvocellular products into the portal vasculature for delivery to 
the AP. For example, synthesis and secretion of gonadotropins is 
controlled by gonadotropin-releasing hormone (GnRH) parvocel-
lular neurons whose axons project to the median eminence where 
GnRH is transported by the portal system to the AP to regulate 
gonadotroph function. In contrast, the magnocellular neurons of 
the paraventricular and supraoptic hypothalamic nuclei project 
their axonal terminals to the PP lobe through the pituitary stalk, 
where they secrete their hormone products, oxytocin (OXT) and 
arginine vasopressin (AVP), directly into the general circulation, 
bypassing in this way any intermediate portal system (13, 14). Of 
note, all neuroendocrine hypothalamic neurons are born within 
the brain, with the exception of the GnRH neurons, which arise 
from the embryonic olfactory pit epithelium and migrate through 
the nose into the brain to reach the hypothalamus.
The ablation of Sox2 in a straightforward knockout mouse 
results in early embryonic lethality soon after implantation, pre-
venting the study of its function during organogenesis (15). Sub-
sequent studies using hypomorphic and Sox2 conditional alleles 
have revealed that severe reduction or complete removal of SOX2 
within the developing neural tube does not cause gross morpho-
logical defects in the brain or spinal cord, possibly due to redun-
dancy with SOX1 and SOX3 (16–19). Despite this, these genetic 
approaches have revealed an essential role for this transcription 
factor in the maintenance of neurons in specific brain regions, 
proliferation and/or maintenance of neural stem cells, and neu-
rogenesis (5, 7, 17, 18). In the pituitary, haploinsufficiency of Sox2 
leads to an overall reduction in gland size with no compromise 
of any hormone-producing cell type and only subtle morphologi-
cal defects, suggesting a likely role for Sox2 either in the hypo-
thalamus, developing pituitary, or both (20). Here, we have used 
a conditional genetic approach to gain insights into its function 
during normal pituitary development and in the pathogenesis of 
the hypopituitarism associated with SOX2 haploinsufficiency in 
humans. Our research has revealed the action of Sox2 at multiple 
levels within the hypothalamic-pituitary axis.
Results
Severe anterior lobe hypoplasia and neonatal lethality in Hesx1Cre/+;Sox2fl/fl 
mutants. We have previously shown that the Hesx1-Cre mouse 
line drives robust Cre-mediated activity in the developing pitu-
itary gland (21, 22). We crossed Hesx1Cre/+ mice with Sox2fl/fl ani-
mals carrying a loxP-Sox2-loxP conditional allele to reveal the 
function of Sox2 during pituitary organogenesis (5). Genotypic 
analysis of 9.5- to 18.5-dpc embryos derived from crosses between 
Hesx1Cre/+;Sox2fl/+ mice and either Sox2fl/+ or Sox2fl/fl animals showed 
no statistically significant variation from the expected Mendelian 
ratios (Supplemental Tables 1 and 2; supplemental material avail-
able online with this article; doi:10.1172/JCI64311DS1). In con-
trast, genotyping of postnatal mice from birth to 3 weeks failed to 
identify any viable Hesx1Cre/+;Sox2fl/fl mice (Supplemental Tables 1 
and 2), demonstrating that deletion of Sox2 using the Hesx1-Cre 
line causes neonatal/perinatal death.
H&E staining of Hesx1Cre/+;Sox2fl/fl mutant pituitaries at 9.5 and 
10.5 dpc revealed no gross morphological defects in the developing 
RP of these mutants compared with those of control littermates 
(Figure 1, A and B, and data not shown). The first clear evidence 
of a morphological defect, typically mild anterior lobe hypopla-
sia, was observed at 12.5 dpc and further pronounced by 14.5 dpc 
(Figure 1, C–F). At 18.5 dpc, a fully penetrant phenotype of severe 
anterior lobe hypoplasia was observed in all embryos analyzed, 
often with remnants of pituitary tissue embedded within the oro-
pharyngeal ectoderm (Figure 1, G–I). As a consequence, normal 
development of the basisphenoid cartilage was disrupted in these 
mutant embryos, so that it remains as 2 separate entities surround-
ing the ectopically located AP tissue (Figure 1I). However, the pos-
terior and intermediate lobes were present and apparently normal 
in Hesx1Cre/+;Sox2fl/fl mutants (Figure 1H). These results suggest 
that early induction of RP occurs normally in Hesx1Cre/+;Sox2fl/fl 
mutant embryos, but subsequently there is a failure of the devel-
oping AP to expand normally, leading to a very small and partially 
ectopic anterior lobe at the end of gestation.
Terminal differentiation of somatotrophs and mature thyro-
trophs is disrupted in Hesx1Cre/+;Sox2fl/fl mutant pituitaries. Specific 
immunostaining against pituitary hormones at 18.5 dpc revealed 
that numbers of somatotrophs (GH+) and thyrotrophs (TSH+) in 
Hesx1Cre/+;Sox2fl/fl mutant pituitaries were substantially reduced, 
accounting for approximately 0.9% and 3.6% of those found in 
matched control pituitaries (Figure 2, A–D, and Supplemen-
tal Figure 1, C and D). However, corticotrophs/melanotrophs 
(ACTH+) and thyrotrophs/gonadotrophs (αGSU+, where αGSU 
indicates α–glycoprotein subunit) were less affected and repre-
sented approximately 42.0% and 36.2% of the numbers identified 
in control pituitaries (Figure 2, I–L, and Supplemental Figure 1, 
A and B). Immunostaining against LH and FSH confirmed the 
presence of gonadotrophs in the Hesx1Cre/+;Sox2fl/fl mutant pitu-
itaries, although these were reduced to 25.8% and 51.5% of the 
numbers identified in controls (Figure 2, M–P). This finding was 
further corroborated by in situ hybridization for Nr5a1 (Sf1), a fac-
tor required for gonadotroph differentiation that precedes FSH 
and LH expression (23, 24), which showed an apparent increase in 
Nr5a1+ cell numbers in the absence of SOX2 (Supplemental Figure 
1, E and F). Finally, PRL immunostaining and in situ hybridization 
using specific Prl antisense riboprobes confirmed that the differ-
entiation of lactotrophs was not as severely impaired as that of 
somatotrophs and thyrotrophs in the mutant pituitary, account-
ing for approximately 31.7% of the PRL+ cells in control pituitaries 
(Figure 2, E and F, and Supplemental Figure 1, G and H).
The transcription factor Pou1f1 is required for normal specifica-
tion of somatotrophs, thyrotrophs, and lactotrophs (Pou1f1 lin-
eage) (25, 26). POU1F1 immunostaining revealed a dramatic reduc-
tion of POU1F1+ cells from 12.5 to 18.5 dpc in the Hesx1Cre/+;Sox2fl/fl 
mutant compared with control pituitaries (Figure 2, G and H, 
and Figure 3, A–D). At 18.5 dpc, numbers of POU1F1+ cells in the 
mutant pituitaries represented a mere 1.4% of those found in con-
trol pituitaries. The emergence of Pou1f1 in the developing pitu-
itary gland relies on Prop1 (prophet of Pou1f1) expression (27–29). 
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In agreement, in situ hybridization analysis revealed a significant 
reduction of the Prop1 expression domain in the mutant pituitar-
ies at 12.5 dpc compared with controls (Supplemental Figure 2, 
C–F). In contrast to POU1F1+ cells, rostral-tip POU1F1-indepen-
dent thyrotrophs as well as corticotrophs, the first 2 differentiated 
cell types that are detectable in the early developing anterior lobe 
(11, 30, 31), were specified in the Hesx1Cre/+;Sox2fl/fl mutant pituitar-
ies, despite the clear reduction in anterior lobe size (Figure 3, E–N). 
In agreement with this finding, expressions of NeuroD1 and Pomc1 
(32, 33), which are 2 markers of the corticotroph and melanotroph 
lineages, were normal or slightly elevated into dorsal regions of 
RP at 12.5 dpc (Supplemental Figure 2, G–J). Lhx3, a marker of 
pituitary cells, was expressed in the dysmorphic and slightly hypo-
plastic pituitary of Hesx1Cre/+;Sox2fl/fl mutants at this stage (Supple-
mental Figure 2, A and B).
Together, these results suggest that (a) absence of Sox2 causes 
severe impairment of somatotroph and mature thyrotroph differ-
entiation, possibly due to a reduction in Prop1 and Pou1f1 expres-
sion at early developmental stages; (b) lactotrophs are present 
in the hypoplastic and dysmorphic pituitary of Hesx1Cre/+;Sox2fl/fl 
mutants to an extent that cannot be accounted for by the sparse 
POU1F1+ cells observed; and (c) this differentiation phenotype 
is related to the timing of cell-cycle exit: rostral-tip thyrotrophs, 
corticotrophs, and gonadotrophs, whose precursors become post-
mitotic from 11.5 dpc are the least affected cell types. In contrast, 
mature thyrotrophs and somatotrophs, which differentiate at later 
developmental stages, are almost absent.
Early induction of RP is not affected in Hesx1Cre/+;Sox2fl/fl mutant embryos. 
Next we sought to assess the possible contribution of aberrant 
hypothalamic signaling to the observed pituitary hypoplasia. Bmp4 
is one of the earliest signaling molecules known to be expressed 
in the presumptive infundibulum and is necessary for the invagi-
nation of RP (34, 35). Fgf8 and Fgf10 are also both expressed in a 
domain similar to that of Bmp4 at this embryonic stage and are 
essential for the maintenance of RP proliferative progenitors 
through the induction of the LIM (zinc finger–containing protein-
protein interaction domain) homeodomain transcription factors 
Lhx3 and Lhx4 (36–39). At 9.5–10.5 dpc, Bmp4, Fgf8, and Fgf10 
expression in ventral diencephalon and Lhx3 induction in RP were 
comparable between genotypes (Supplemental Figure 3, A–F, I, and 
J). In addition, immunostaining against the phosphorylated form 
of MAPK1 (ERK1/2), a readout of active FGF signaling, revealed 
similar staining in the developing RP of Hesx1Cre/+;Sox2fl/fl mutants 
and control littermates (Supplemental Figure 3, G and H). Togeth-
er, this analysis demonstrates that the initial steps of pituitary 
development are not affected in Hesx1Cre/+;Sox2fl/fl mutants.
At 12.5 dpc, expression of both Bmp4 and Fgf8 in the hypothal-
amus is thought to be required for the maintenance of RP pro-
genitors and, specifically Fgf8, for the inhibition of ventral (i.e., 
thyrotrophs) and promotion of dorsal (i.e., corticotrophs) fates 
(34–37). No evident differences were observed in the expression 
domains of these 2 signaling molecules within the hypothalamus 
of Hesx1Cre/+;Sox2fl/fl mutants and controls (Supplemental Figure 3, 
K–N). However, the Lhx3 expression domain was clearly reduced 
in the mutant pituitaries (Supplemental Figure 2, A and B), sug-
gesting a failure of the RP periluminal progenitors to proliferate, 
despite the presence of hypothalamic signals.
The relatively late onset of pituitary defects observed in the 
Hesx1Cre/+;Sox2fl/fl embryos prompted us to evaluate the temporal 
and spatial efficiency of Cre-mediated excision of the Sox2 con-
ditional allele in these embryos. Immunostaining revealed com-
parable levels of SOX2 in the developing RP and overlying dien-
cephalon in Hesx1Cre/+;Sox2fl/+ control and Hesx1Cre/+;Sox2fl/fl mutant 
embryos at 10.5 dpc, demonstrating persistence of SOX2 protein 
at this early stage (Supplemental Figure 4, A and B). However, at 
12.5 dpc, there was a drastic reduction in SOX2 within RP peri-
Figure 1
Abnormal pituitary morphogenesis and severe anterior lobe 
hypoplasia in Hesx1Cre/+;Sox2fl/fl mutant mice. H&E stain-
ing of sagittal (A–F) or transverse (G–I) histological sections 
from Hesx1Cre/+;Sox2fl/+ control and Hesx1Cre/+;Sox2fl/fl mutant 
embryos. (A and B) No significant differences in the mor-
phology of RP and ventral diencephalon (VD) are observed 
between genotypes at 9.5 dpc. (C and D) By 12.5 dpc, the 
infundibulum (Inf), a depression of the floor of the ventral dien-
cephalon, RP periluminal epithelium, and the developing AP 
are clearly distinguishable in a control embryo (C). However, 
RP and developing AP are dysmorphic and slightly hypoplastic 
in the mutant embryo (D). (E and F) At 14.5 dpc, a substan-
tial AP has developed over the basisphenoid (BS) bone in the 
control embryo (E), but AP is dysmorphic, small, and ectopi-
cally located between the developing unfused basisphenoid 
cartilages in the mutant pituitary (F). (G–I) At 18.5 dpc, the 
pituitary gland is situated between the hypothalamus (Hypo) 
and basisphenoid and comprises the posterior, intermediate, 
and anterior lobes (PL, IL, and AL, respectively) in a control 
embryo (G). In the mutant pituitary, posterior lobes and inter-
mediate lobes are morphologically distinguishable, but only a 
rudiment of the anterior lobe is observed, often lying between 
the unfused basisphenoid and in contact with the oropharyn-
geal cavity (OR). H and I show sections at different axial levels 
of the same embryo. Scale bars: 100 μm.
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luminal progenitors in Hesx1Cre/+;Sox2fl/fl developing pituitaries 
compared with controls, despite similar levels in the prospective 
hypothalamus and infundibulum (Supplemental Figure 4, C–F). 
Absence of SOX2 staining was also confirmed in the anterior and 
intermediate lobes of the mutant pituitary at 18.5 dpc (Supple-
mental Figure 4, G and H). This pattern of SOX2 deletion fits 
with the observed Cre-mediated activity in the Hesx1Cre/+;R26YFP/+ 
embryos, as robust and abundant yellow fluorescent protein (YFP) 
expression is detected throughout the RP and developing pituitary 
gland with mosaic YFP reactivity in the infundibulum, ventral 
hypothalamus, telencephalon, olfactory epithelium (OE), and oral 
ectoderm (Supplemental Figure 4, I–N, and refs. 21, 22). Together, 
these data suggest that a significant loss of SOX2 does not occur 
at the early stages of RP specification in the Hesx1Cre/+;Sox2fl/fl 
mutants, which explains the lack of phenotype at 10.5 dpc. In 
addition, our results suggest that abnormal hypothalamic signal-
ing is not an important contributor to the hypoplastic pituitary 
phenotype observed at late gestation, but rather, that it is the con-
sequence of the loss of Sox2 within the developing RP.
Reduced proliferation of RP progenitors in Hesx1Cre/+;Sox2fl/fl embryos. 
The observed hypoplasia of the AP in the Hesx1Cre/+;Sox2fl/fl mutants 
could be due to increased apoptosis of RP progenitors/differentiat-
ed cells, decreased proliferation, premature differentiation, and/or 
a combination of these factors.
Cell death normally occurs within the oral ectoderm closely adja-
cent to the developing RP, where it is thought to play a role in mor-
phogenesis, to aid the separation of RP from the oral epithelium at 
11.5–12.5 dpc (40). Staining against cleaved caspase-3 revealed the 
presence of apoptotic cells in this area of the oral ectoderm in both 
mutant and control embryos, but no significant differences in stain-
ing were observed within the body of the mutant and control devel-
oping pituitaries between 12.5 and 14.5 dpc (Supplemental Figure 5).
Recent studies have demonstrated essential roles for the nega-
tive cell-cycle regulators CDK1NC and CDK1NB (p27Kip1) in the 
control of cell-cycle exit of pituitary cell lineage precursors and 
terminal differentiation of hormone-producing cells, respectively 
(12). Specific immunostaining revealed no major differences in 
the expression pattern of CDK1NC between genotypes at 12.5 and 
14.5 dpc (Supplemental Figure 6, I–L). However, a modest but con-
sistent increase in CDK1NB was observed in the Hesx1Cre/+;Sox2fl/fl 
mutant pituitaries relative to stage-matched controls (Supplemen-
tal Figure 6, M–P). Premature differentiation was further assessed 
in the mutant pituitaries by analyzing the expression of the early 
lineage commitment markers ACTH, αGSU, and TBX19 (T-pit) at 
developmental stages immediately prior to when gene expression 
can first be detected in normal control embryos. These analyses 
failed to reveal any difference in the temporal expression of these 
markers in the developing anterior lobe (Supplemental Figure 6, 
A–H). Mouse embryos deficient for the Notch downstream tar-
get gene Hes1 display a concomitant increase in both CDK1NC 
and CDK1NB without relevant changes in differentiation marker 
expression (41). Therefore, precocious cell-cycle exit may not be 
indicative of premature cellular differentiation. Together, these 
data imply that increased cell death or premature differentiation 
are not important contributors to the AP hypoplasia observed in 
Hesx1Cre/+;Sox2fl/fl embryos.
Figure 2
Defective terminal differentiation of specific hormone-producing cell types in Hesx1Cre/+;Sox2fl/fl pituitaries at late gestation. Immunohistochemistry 
with specific antibodies against GH, TSH, PRL, POU1F1, ACTH, αGSU, FSH, and LH on transverse histological sections of Hesx1Cre/+;Sox2fl/+ 
control and Hesx1Cre/+;Sox2fl/fl mutant embryos. Note the severe reduction of somatotrophs (GH+) (A and B), thyrotrophs (TSH+) (C and D), and 
POU1F1+ cells (G and H) in the mutant pituitary relative to the controls (arrowheads indicate expressing cells in B and D). Despite the drastic 
hypoplasia of the anterior lobe, lactotrophs (PRL+) (E and F), corticotrophs, and melanotrophs (ACTH+) (I and J) as well as gonadotrophs (FSH+, 
LH+,and αGSU+) (K–P) are present. Scale bars: 100 μm.
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Next, we analyzed proliferation of RP progenitors at 12.5 dpc, just 
as a morphological phenotype becomes noticeable, and 14.5 dpc, 
when anterior lobe hypoplasia is fully evident. Cyclin D2 con-
trols G1/S cell-cycle progression and is mainly expressed in RP 
progenitors in the periluminal epithelium (12). Quantification 
of cyclin D2–expressing cells out of total DAPI-stained nuclei in 
the periluminal epithelium revealed a significant decrease in this 
ratio in the Hesx1Cre/+;Sox2fl/fl mutant pituitary compared with 
stage-matched controls (Figure 4, A–E). Actively dividing cells 
can also be detected by a short pulse (90 minutes) of BrdU, which 
is incorporated during DNA replication at the S-phase of the cell 
cycle. In the pituitary gland, it is well established that BrdU-
labeled cells are mostly detected in RP progenitors lining the 
cleft when the pulse is administered from 12.5 dpc to 14.5 dpc 
(11, 12). Quantitative analysis showed a significant reduction 
of total numbers of BrdU+ cells relative to DAPI-stained nuclei 
in mutant relative to control pituitaries at both stages analyzed 
(Figure 4, F–J). Therefore, lack of SOX2 in RP progenitors leads 
to a decreased proliferation rate during the developmental win-
dow when progenitors of the majority of the anterior lobe hor-
mone-producing cells exit the cell cycle (11).
We reasoned that this significant reduction in the prolifera-
tive capacity of early RP periluminal progenitors could account, 
at least partially, for the observed phenotype whereby only ante-
rior lobe differentiated cells (i.e., corticotrophs, rostral-tip thyro-
trophs, and gonadotrophs) whose precursors exit cell cycle early 
are present, while cells derived from late precursors (i.e., somato-
trophs and mature thyrotrophs) are missing. To test this concept 
further, we carried out a pulse/chase BrdU experiment by injecting 
a single dose of BrdU into pregnant mice at 10.5 dpc and analyzing 
the embryos at 14.5 dpc. This temporal window was expected to 
allow actively proliferating 10.5-dpc RP progenitors to go through 
Figure 3
Corticotrophs and rostral-tip POU1F1-independent thyrotrophs are specified in Hesx1Cre/+;Sox2fl/fl developing pituitaries, but POU1F1 expression 
is not initiated during embryonic development. Immunofluorescent detection of specific cell lineage marker expression on sagittal (A, B, and I–N) 
and transverse histological sections (C–H) of Hesx1Cre/+;Sox2fl/+ control and Hesx1Cre/+;Sox2fl/fl mutant embryos at 14.5 and 15.5 dpc. (A and B) 
POU1F1+ cells are abundant in the caudomedial region of the control (A), but are not detected in the mutant (B) AP at 14.5 dpc. (C and D) A 
day later, most of the cells in the anterior lobe express POU1F1 in the control (C). However, the mutant pituitary is devoid of POU1F1+ cells (red 
signal is autofluorescence by blood cells) (D). (E–H) Despite the evident hypoplasia, ACTH+ and αGSU+ cells are detected at large numbers in 
the mutant (F and H) pituitary. The red signal around the PP area is due to blood cells in G and H. (I and L) TSH+ cells corresponding with the 
rostral-tip POU1F1-independent thyrotrophs are identified in the control (J) and mutant (M) developing anterior lobe. However, the TSH+ cells 
marking the POU1F1-dependent thyrotrophs, located in caudomedial regions, can be recognized only in the control (K), but not in the mutant (N), 
pituitary. The autofluorescence signal in N is due to trapped blood cells. Scale bars: 100 μm.
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Figure 4
Reduced cell proliferation of RP periluminal progenitors in Hesx1Cre/+;Sox2fl/fl embryos. The region of the periluminal epithelium used for quantitative 
analysis is delineated in A–I. (A–D) Cyclin D2 immunofluorescence identifies cycling cells at the G1/S transition in RP, but not in the developing AP, 
at 12.5 and 14.5 dpc in both genotypes. (E) Quantitative analysis demonstrates a significant decrease in cycling cells in the mutant compared with 
the control pituitaries at both stages analyzed (12.5 dpc, **P = 0.0011; 14.5 dpc, ***P < 0.0001; Student’s t test). (F–I) BrdU immunodetection after 
a 90-minute pulse showing the presence of cycling cells in S phase mainly within the RP periluminal epithelium in both genotypes. PITX1 staining 
distinguishes pituitary tissue from surrounding mesenchyme. (J) There is a significant reduction in the percentage of BrdU+ cells from the total 
PITX1-stained nuclei in the mutant relative to the control pituitaries (12.5 dpc, *P = 0.0252; 14.5 dpc, ***P = 0.0001; Student’s t test). (K–L) BrdU 
and PITX1 double immunostaining on control (K) and mutant (L) pituitaries. BrdU was injected at 10.5 dpc and labeled cells traced at 14.5 dpc. 
In the control pituitary, BrdU labeling is strong in the rostral-tip and ventromedial region of the AP, weak in the dorsomedial region, and almost 
absent in the periluminal epithelium. In the mutant pituitary, BrdU retention in the periluminal epithelium is evident and a dorsomedial region of weak 
BrdU signal is not clearly observed. (M) There is a significant increase in BrdU retention in the mutant relative to the control pituitaries (*P = 0.0158; 
Student’s t test). Scale bars: 100 μm.
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several cell cycles, thereby diluting the marker through subsequent 
S-phases in half with each division. In contrast, early born cells 
exiting the cell cycle around the time of BrdU injection, and not 
further dividing, would retain a steady level of marker. In control 
14.5-dpc embryos, as expected, most of the strongly stained BrdU+ 
cells were located in the rostral tip of the gland, corresponding 
to the rostral-tip POU1F1-independent thyrotrophs and cortico-
trophs (Figure 4K and refs. 11, 30). In these embryos, BrdU staining 
was not detected in the periluminal epithelium containing RP pro-
genitors, as subsequent rounds of divisions would have diluted the 
initially incorporated label. An intermediate zone of the anterior 
lobe immediately ventral to the periluminal space, where POU1F1+ 
cells normally reside, showed weaker BrdU incorporation, as these 
cells exit the cell cycle later in development (Figure 4K). This BrdU 
staining pattern created a distinct visual gradient in the control 
pituitaries that was not as well defined in the Hesx1Cre/+;Sox2fl/fl 
mutant littermates. Rather, there was more uniform BrdU staining 
throughout the hypoplastic anterior lobe of the mutant pituitary 
containing the rostral-tip thyrotrophs and corticotrophs, as previ-
ously shown (Figure 4L). Consistently, BrdU+ cells remained in the 
ventral part of the periluminal epithelium, indicating that these 
progenitors had retained the label for longer. Quantification of 
the ratios between BrdU+ cells/total DAPI-stained nuclei revealed 
a significant increment in the mutant pituitaries compared 
with controls (Figure 4M). The pattern of BrdU staining in the 
Hesx1Cre/+;Sox2fl/fl mutant developing pituitary is consistent with 
the marked defects previously described in POU1F1 cell lineage 
specification and less affected corticotroph and rostral-tip thyro-
troph differentiation. In addition, the persistence of BrdU-labeled 
cells in RP periluminal progenitors is compatible with the lower 
proliferation capacity observed in the mutant pituitary at 12.5 
and 14.5 dpc. In summary, these studies demonstrate an essential 
requirement for Sox2 during proliferation of RP progenitors and 
expansion of the AP.
Figure 5
Significant reduction of GnRH neurons in the brain and nasal regions of Hesx1Cre/+;Sox2fl/fl mutant embryos. (A and B) Specific immunostaining 
shows the accumulation of GnRH in the axon terminals of GnRH neurons in the median eminence (ME) of the control (A), but not the mutant 
hypothalamus, at late gestation (B). (C and D) Representative pictures of GnRH neurons (arrowheads) in the brain at the level of the medial pre-
optic area. (E) Quantitative analysis of total numbers of GnRH neurons in the brain of both genotypes at 18.5 dpc (n = 2 per genotype). (F and G) 
Representative pictures of migrating GnRH neurons in the nasal area (NA; arrowheads) and forebrain (FB; arrows) at 13.5 dpc. (H) Quantitative 
analysis of total numbers of GnRH neurons in the heads of embryos of both genotypes (n = 3 per genotype; *P = 0.011; Student’s t test). (I–L) At 
12.5 dpc, GnRH neurons are detected around the OE (arrowheads) and are migrating toward the forebrain (arrows) in the control embryo (I and K) 
(n = 2). There is an evident reduction in the mutant embryo (J and L) (n = 2). Scale bars: 100 μm; 10 μm (insets).
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Lack of GnRH neurons in the hypothalamus of Hesx1Cre/+;Sox2fl/fl 
mutant embryos. Given that gonadotrophs were present at consid-
erable numbers in the pituitaries of the Hesx1Cre/+;Sox2fl/fl mutant 
embryos, we sought to explore whether defects in the neuroendo-
crine hypothalamic nuclei may account for the HH observed in 
patients carrying SOX2 mutations.
In situ hybridization with specific Avp and Oxt antisense ribo-
probes revealed the presence of these neurons within the para-
ventricular and supraoptic nuclei of Hesx1Cre/+;Sox2fl/fl mutant 
and control 18.5-dpc embryos (Supplemental Figure 7, A–H, and 
refs. 13, 14). Likewise, similar Ghrh and Nr5a1 expression domains 
in the arcuate and ventromedial nuclei, respectively, were observed 
in Hesx1Cre/+;Sox2fl/fl mutants and controls at 18.5 dpc (Supplemen-
tal Figure 7, I–L). Finally, immunostaining against GnRH at this 
stage revealed an expected pattern of expression in the median emi-
nence of the hypothalamus in control embryos (Figure 5A). In con-
trast, an evident lack of GnRH immunoreactivity was apparent in 
the median eminence of the Hesx1Cre/+;Sox2fl/fl mutants (Figure 5B). 
In keeping with this finding, quantitative analysis revealed a 
substantial reduction of GnRH neurons in the Hesx1Cre/+;Sox2fl/fl 
mutant brain when compared with controls at 18.5 dpc (control 
583.5 ± 60.50, mutant 269.0 ± 44.00; n = 2; Figure 5, C–E). This 
reduction was also observed at 12.5 dpc and 13.5 dpc, when GnRH 
neurons migrate from the OE to the brain (Figure 5, F–L). Of 
note, numbers of migrating GnRH neurons within the nasal area 
were significantly reduced, suggesting that the initial defect may 
be in the neurogenesis of this cell type (Figure 5H). Collectively, 
these data suggest that the neuroendocrine hypothalamus of the 
Hesx1Cre/+;Sox2fl/fl embryos is not overtly affected, but rather, gen-
eration of GnRH neurons is significantly impaired and projections 
to the median eminence completely absent.
Human patients harboring SOX2 mutations respond to GnRH stimulation. 
The data derived from the mouse model imply that reduced GnRH 
neurogenesis may account for the HH observed in patients harbor-
ing SOX2 heterozygous mutations. We sought to explore our find-
ings further by assessing the responses to a GnRH stimulation test 
of 2 patients carrying mutations in SOX2.
Patient 1 harbored a missense mutation in SOX2 (p.L97P) that 
leads to loss of DNA binding with impaired transactivation (20) 
and was previously reported (42). She had bilateral microphthal-
mia with left sclerocornea and aphakia. At the age 
of 12 years, a GnRH stimulation test showed poor 
response, with a peak LH of 3.1 IU/l and peak FSH 
of 4.0 IU/l 60 minutes after GnRH stimulation. Two 
years later, she had a height of 138.4 cm (–2.65 SD 
score) with a weight of 32.5 kg (–1.6 SD score). She 
was completely prepubertal; the uterus was prepu-
bertal and neither ovary was identified on ultrasound 
imaging. MRI revealed right microphthalmia with a 
prosthesis in situ, a colobomatous left globe, small 
optic nerves, and chiasm, a normal AP, and a thick-
ened upper third of the pituitary stalk. Investiga-
tions revealed a normal free thyroxine, cortisol, IGF1, 
IGFBP3, and peak GH to glucagon stimulation. The 
PRL concentration was low (Supplemental Table 3). 
GnRH testing was repeated using 2 different i.v. doses 
(100 and 500 μg); the initial injection of GnRH caused 
an increase in circulating concentrations of FSH (from 
0.4 to 3.6 IU/l) and LH (from <0.2 to 2.8 IU/l) after 
1 hour (Figure 6). FSH concentrations were further 
increased after a second higher dose of GnRH, reaching a peak of 
4.8 IU/l. In contrast LH concentrations were no further elevated 
after a second injection; indeed, there was a decrease.
Patient 2, with a haploinsufficient c.60insG SOX2 mutation, was 
previously described with bilateral anophthalmia, learning diffi-
culties, and oesophageal atresia (20). She was noted to have iso-
lated HH, with a low response to GnRH stimulation (peak LH of 
6.1 IU/l and FSH of 5.7 IU/l, both at 60 minutes after GnRH stim-
ulation). Measurement of overnight spontaneous LH and FSH 
concentrations revealed impaired FSH and LH secretion (FSH 
3.2-4.7 IU/l and LH 1-2 IU/l) with no pulsatility. Peak GH to glu-
cagon stimulation was normal. Pubertal induction was performed 
using ethinylestradiol. More recently, the ethinylestradiol was 
stopped, and GnRH testing was repeated using a dose of 100 μg 
followed by 500 μg as performed with patient 1. There was a dra-
matic increase in LH concentration, from 2.5 to 29.7 IU/l, with an 
increase in FSH from 6.0 to 16.2 IU/l following the administration 
of 100 μg GnRH, with a further increase in LH to 32.1 IU/l and 
FSH to 22.0 IU/l following the administration of the higher dose 
of GnRH. Both IGF1 and IGFBP3 are low at the time of writing 
(Supplemental Table 3), suggesting the possibility of adult GH 
deficiency, although cortisol and thyroid function tests as well as 
the PRL concentrations are normal.
The responses in both patients are in keeping with former stud-
ies (43–46), and in particular, that of the second patient suggests 
that functional gonadotrophs that are able to receive the GnRH 
signal and secrete gonadotrophins are present in the pituitary 
gland, even if this is hypoplastic on MRI evaluation.
Discussion
Human patients carrying heterozygous SOX2 mutations com-
monly display a phenotype characterized by AP hypoplasia on 
imaging (1, 4, 20, 47, 48). However, most pituitary hormones are 
detected at normal concentrations, with the exception of occa-
sional GH deficiency; on the other hand, the gonadotrophins 
FSH and LH are present at abnormally low concentrations, 
causing typical HH (1, 2, 10, 45, 46). HH may be present even in 
patients without pituitary hypoplasia, suggesting that there may 
be a specific requirement of SOX2 for normal development of 
the hypothalamic-gonadotroph axis (49). Since the pathogenesis 
Figure 6
Gonadotrophin responses to GnRH stimulation in 2 female patients harboring 
heterozygous SOX2 mutations. A bolus of 100 mg of GnRH was administered i.v. 
(first arrow) and LH and FSH measured at 0, 30, and 60 minutes. This was followed 
by a second injection of 500 mg of GnRH (i.v. bolus; second arrow) and further half-
hourly measurements for 4 hours. Note the elevation of both LH and FSH circulating 
concentrations in both patients. Patient 1 received the second bolus 1 hour after the 
first one, while patient 2 had a lag of 2 hours between injections.
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of these abnormalities in the patients is poorly understood, the 
analysis of the Hesx1Cre/+;Sox2fl/fl mouse model presented here has 
proven helpful in the investigation of the mechanisms underlying 
the phenotype of these patients.
Providing a possible explanation for the anterior lobe hypo-
plasia frequently observed in human patients, our data dem-
onstrate that SOX2 plays a critical role in the regulation of cell 
proliferation in RP periluminal progenitors during early devel-
opment (Figure 4). The consequence of this proliferation defect 
is the generation of a small pool of undifferentiated cell lineage 
precursors, which is insufficient to allow the subsequent differ-
entiation of enough numbers of hormone-producing cells at late 
gestation, resulting in severe pituitary hypoplasia. The predic-
tion of this phenotype is that precursors of those cell lineages 
that exit cell cycle and begin differentiation earlier should be 
less affected than precursors of lineages that stop cycling later in 
development. In agreement with this notion, our data show that 
rostral-tip thyrotrophs, corticotrophs, and gonadotrophs, whose 
precursors become postmitotic from 11.5 dpc are present in the 
Hesx1Cre/+;Sox2fl/fl mutant pituitary at late gestation, but somato-
trophs and POU1F1-dependent thyrotrophs, which represent 
late-born cell types, are drastically reduced in numbers (Figure 2, 
Supplemental Figure 1, and refs. 10, 11). Therefore, it seems rea-
sonable to suggest that similar cellular defects may underlie the 
typical pituitary hypoplasia observed in patients carrying SOX2 
mutations, although the severity may be attenuated due to the 
presence of a wild-type SOX2 allele in these patients. Supporting 
this notion, some patients with SOX2 mutations manifest GH 
deficiency (in addition to the typical HH), suggesting a specific 
defect in somatotrophs (50, 51). In mouse, somatotrophs are the 
last hormone-producing cell type of the anterior lobe to be born 
and therefore, are possibly more susceptible if not enough pre-
cursors are generated at early stages of pituitary development, as 
our data from the mouse model demonstrate. Therefore, the pro-
pensity of human patients carrying SOX2 mutations to develop 
GH deficiency may be caused by a reduced pool of progenitors in 
the developing pituitary.
The analysis of our mouse model gives relevant clues on the 
molecular alteration causing this phenotype. We show an almost 
complete absence of POU1F1 and a drastic downregulation of 
Prop1 expression in Hesx1Cre/+;Sox2fl/fl developing pituitaries (Fig-
ures 2 and 3 and Supplemental Figure 2). Reduction in Prop1 
expression could be the consequence of fewer cells present to 
commit to this fate, due to a reduced precursor pool (27, 52–54), 
or alternatively, impaired Prop1 gene activation in the absence of 
SOX2 (55). In Prop1–/– mutants, there is a significant reduction in 
proliferation of RP progenitors, which upon cell-cycle exit fail to 
migrate into the developing anterior lobe (56). The similarities of 
these phenotypes suggest that the proliferation defects observed 
in the Hesx1Cre/+;Sox2fl/fl developing pituitaries may be the additive 
result of reduced Sox2 and Prop1 functions. Furthermore, condi-
tional removal of the Notch intracellular mediator recombination 
signal-binding protein for immunoglobulin κ J region (RBPJ), 
leading to the complete genetic ablation of Notch signaling, results 
in severe AP hypoplasia, with the concomitant reduction of Prop1 
expression and the POU1F1 cell lineage (57). Similarly, absence of 
the Notch targets Hes1 and Hes5 also results in AP hypoplasia due 
to reduced proliferative capacity of RP progenitors (41, 58, 59). 
Of interest, Notch signaling has been found to function down-
stream of Sox2 within neural progenitor cell populations, such as 
the developing neural tube and retina (5, 60). Thus, it seems likely 
that SOX2 may mediate part of its function through the control of 
Notch signaling and Prop1 expression within the pituitary.
It is not obvious why the Hesx1Cre/+;Sox2fl/fl mice die perinatally, 
but we may assume that the disruption of the basisphenoid carti-
lage could compromise breathing and suckling of these neonates. 
Alternatively, loss of mature thyrotrophs required for lung matu-
ration may further contribute to this phenotype, as previously 
shown in the Prop1–/– mutants (52). An unexpected finding is the 
presence of lactotrophs in the Hesx1Cre/+;Sox2fl/fl mutant pituitary at 
late gestation, despite the severe reduction of POU1F1 expression 
from the early onset (Figure 2 and Supplemental Figure 1). Do they 
represent a POU1F1-independent lactotroph lineage? Analysis of 
the Snell mouse model, which harbors a mutation in the Pou1f1 
gene, led to the identification of an independent thyrotroph popu-
lation, not reliant on the former expression of Pou1f1, but lacto-
trophs were not analyzed (30). Prl transcriptional activation in the 
absence of Pou1f1 has previously been reported in a cell line (61), 
and our data provide support to the concept that there may be a 
POU1F1-independent lactotroph cell population in the pituitary 
at late gestation. Previously, it has been shown that lactotrophs, 
identified by PRL expression, are detectable as early as 14.0 dpc in 
the developing mouse pituitary, concurrently with caudomedial 
POU1F1-dependent thyrotrophs and followed by somatotrophs at 
16.0 dpc (10). Therefore, it is also possible that the sparse POU1F1+ 
cells detected in the Hesx1Cre/+;Sox2fl/fl pituitaries may be biased to a 
lactotroph fate, as they appear to be the first cells to be born in this 
lineage. However, the observation that lactotrophs are more abun-
dant than POU1F1+ cells in the Hesx1Cre/+;Sox2fl/fl mutant pituitary 
argues against this possibility. Whether POU1F1 may be required 
in vivo only for the initiation of Prl expression and not for its main-
tenance is a question that requires further analyses of PRL expres-
sion in other mouse models deficient for either Prop1 or Pou1f1.
Our studies raise an important question: if gonadotrophs are 
present in humans carrying SOX2 mutations, what is the cause 
of the HH commonly manifested in these patients? Terminal dif-
ferentiation of gonadotrophs, as assessed by expression of FSH 
and LH, occurs in Hesx1Cre/+;Sox2fl/fl mutant embryos (Figure 2 and 
Supplemental Figure 1), suggesting that in the patients, the HH 
is not of pituitary origin. As it is well established that gonado-
troph function is reliant upon the inducing actions of hypo-
thalamic GnRH neurons, either a loss of these neurons or their 
misdirected migration from their origin of the olfactory placode 
could underlie this condition in humans. Our data demonstrate 
a substantial reduction of GnRH neurons in the Hesx1Cre/+;Sox2fl/fl 
embryos at all stages analyzed (Figure 5). This defect is specific 
to GnRH neurons, as other neurons within the neuroendocrine 
hypothalamus (AVP+, OT+, and GHRH+) are not affected (Supple-
mental Figure 7). In addition to reduced GnRH numbers, axonal 
projections may be misdirected, as evidenced by the almost com-
plete lack of GnRH immunostaining in the median eminence of 
Hesx1Cre/+;Sox2fl/fl embryos (Figure 5). While patients with SOX2 
haploinsufficiency, and therefore 1 normal SOX2 allele, may be 
expected to have higher numbers of GnRH neurons than our 
mouse model, our findings suggest that these neurons may not 
fully project their axons to the median eminence, resulting in a 
failure of gonadotroph stimulation and gonadotrophin produc-
tion. Supporting this hypothesis, we show that 2 patients carrying 
inactivating heterozygous mutations in SOX2 and manifesting 
HH can respond to GnRH stimulation (Figure 6). This implies 
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PCR on tail-tip biopsies digested in DNAreleasy (Anachem) from mice and 
embryos using specific primers. The data presented here are representative 
examples of at least 3 individual embryos per genotype.
H&E and section in situ hybridization. Histological processing of embryos, 
H&E, and in situ hybridization on paraffin sections were performed as 
previously described (63, 64). The antisense riboprobes used in this study 
have previously been described (14, 22, 63, 64), with the exception of Fgf10, 
which was generated from a construct containing the Fgf10 cDNA.
BrdU labeling and immunostaining. For BrdU labeling, pregnant mice were 
injected intraperitoneally with BrdU (100 mg/kg body mass), sacrificed as 
required thereafter (see text for details), and embryos fixed in 4% PFA and 
processed for immunodetection as follows: 6- to 8-μm paraffin sections 
were blocked in 5% heat-inactivated sheep serum in TBS/0.1% Tween-20 
after antigen retrieval and incubated with primary antibodies overnight at 
4°C and with secondary antibodies (either HRP- or fluorochrome-coupled) 
for 1 hour at room temperature. For immunostaining of GnRH neurons 
at E18.5, 16-μm cryosections were serially cut from the entire brain and 
immunostained as previously described (65). The anti-POU1F1 antibody was 
a gift from Simon Rhodes (Department of Cellular and Integrative Physiol-
ogy, Indiana University School of Medicine, Indianapolis, Indiana, USA), and 
Jacques Drouin (Molecular Genetics Research Unit, Institut de Recherches 
Cliniques de Montréal, Montréal, Quebec, Canada) provided us with the anti-
TBX19 and anti-PITX1 antibodies. Working dilutions and sources of other 
antibodies used in this study have previously been detailed (22, 31, 65–67). 
For quantification of hormone-producing cells at 18.5-dpc, 2 control and 2 
mutant pituitaries were analyzed using specific antibodies as described (22). 
Depending on the cell type, 2–7 histological sections from Hesx1Cre/+;Sox2fl/fl 
mutant and control pituitaries were counted, and proportions were calcu-
lated as the percentage of cell numbers in the mutant versus the control pitu-
itary. Numbers of counted cells were as follows: (a) 5010 GH+, 2478 TSH+, 
3533 ACTH+, 2155 αGSU+, 414 LH+, 239 FSH+, and 6177 POU1F1+ in con-
trol pituitaries; (b) 43 GH+, 90 TSH+, 1483 ACTH+, 780 αGSU+, 107 LH+, 
123 FSH+, and 88 POU1F1+ in Hesx1Cre/+;Sox2fl/fl mutants.
Cell proliferation studies. Cyclin D2–expressing and BrdU+ cells, after 
a short pulse (90 minutes) within the periluminal epithelium, which 
contains rapidly dividing embryonic progenitors, were quantified in 
Hesx1Cre/+;Sox2fl/fl mutant and staged-matched controls. Three and 6 non-
consecutive histological sections were analyzed per embryo at 12.5 dpc 
and 14.5 dpc, respectively. Figures are represented as the percentage of 
positive cells from the total DAPI-stained nuclei (cyclin D2 labeling) or 
PITX1-expressing cells (BrdU labeling). This equated to approximately 
400 nuclei per pituitary at 12.5 dpc and 350 nuclei at 14.5 dpc, and 3 con-
trol and mutant pituitaries were analyzed. For the BrdU label retention 
experiments, entire pituitaries were counted in both control (∼700 nuclei) 
and mutant (∼550 nuclei) embryos.
Statistics. For Mendelian ratio analyses, χ2 tests were used. For all other 
analyses, 2-tailed Student’s t tests were used to assess the differences 
between genotypes. SEM and P values were derived from a minimum of 3 
pituitaries per condition. A P value of less than 0.05 was considered statisti-
cally significant. All quantitative data are presented as the mean ± SEM.
Study approval. All the experiments performed in mice were reviewed and 
approved by an internal ethical review committee at University College 
London and ratified by the UK government.
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that functional gonadotrophs, able to bind injected GnRH and 
secrete FSH and LH, are present in these patients, but normal 
hypothalamic control is disrupted. All the patients from previous 
studies showed poor response to GnRH stimulation, similar to 
that of patient 1 in this study (4, 20, 49, 51). What we find very 
interesting and revealing is that when patient 2 was initially test-
ed several years ago at a prepubertal stage, she showed a blunted 
response like that of patient 1 (20). However, when the test was 
repeated after estrogen treatment, the response to this stimula-
tion test was essentially normal, possibly indicating a priming 
effect by estrogen (Figure 6). This finding reinforces our conclu-
sion that gonadotrophs are present and functional in this patient 
and, in addition, it suggests that administration of GnRH may 
be useful in inducing puberty in patients with SOX2 mutations.
Although this finding provides an explanation for the human 
phenotype observed, the mechanism underlying this defect 
remains unclear. A reduced dose of SOX2, as in Sox2hyp/– embryos 
(carrying a lower dose of Sox2), results in diminished neurogen-
esis, but the specification of all OE neuronal cell types, including 
olfactory, vomeronasal, and GnRH neurons, occurs as normal, 
albeit resulting in reduced numbers (5, 62). Moreover, these neu-
rons are detected within the OE, nasal cavity, and forebrain of the 
hypomorphic mutants, implying that migration is not completely 
impaired. It is possible that the deletion of SOX2 within the OE of 
the Hesx1Cre/+;Sox2fl/fl mouse results in a partial reduction of neu-
rogenesis, which ultimately accounts for the reduced GnRH neu-
rons seen at late gestation. The detection of Cre-mediated reporter 
activity within the OE of Hesx1Cre/+;R26YFP/+ mice supports this pos-
sibility (Supplemental Figure 4 and ref. 21).
There are some similarities as well as differences between the 
phenotypic features of patients with SOX2 mutations and those 
in our mouse model. In humans, SOX2 haploinsufficiency dis-
rupts the hypothalamic-gonadotrophic axis and leads to HH in 
all patients analyzed, and only occasionally, patients show GH 
deficiency, suggesting an additional impairment of the hypotha-
lamic-somatotrophic axis. The mouse and human data present-
ed here demonstrate that the HH is of hypothalamic and not 
pituitary origin. Unfortunately, we could not assess the nature 
of the GH deficiency in the patients for ethical reasons, but the 
mouse data strongly suggest that the underlying cause is likely 
to be an impairment of somatotroph differentiation rather than 
a deficit of GHRH neurons. Adrenal function and PRL concen-
trations are mostly normal in patients with SOX2 mutations, 
and in the mouse, we show that ACTH- and PRL-expressing 
cells are present in abundant numbers. A major difference is 
that thyrotrophs are severely affected in the mouse model, but 
in humans, thyrotroph function is normal. We believe differ-
ences in the penetrance and severity of the phenotype are par-
tially due to a SOX2 dosage effect, as previously demonstrated 
(5), as humans have a wild-type SOX2 allele, whereas there is 
no expression of SOX2 in the mouse model. In conclusion, the 
data presented here have revealed important insights into the 
pathogenic mechanisms underlying the endocrine phenotype 
observed in patients with SOX2 mutations.
Methods
Mice. The Hesx1Cre/+ and Sox2fl/+ mouse lines have previously been described 
(5, 21). Sox2fl/+ were crossed with Hesx1Cre/+ animals in order to generate 
Hesx1Cre/+;Sox2fl/+ mice. These mice were used for mating with either Sox2fl/fl 
or Sox2fl/+animals. Genotyping of mice and embryos was carried out by 
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